TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of new inhalation products for the treatment of chronic respiratory diseases and lung conditions. In early testing, the Thin Film Freezing (TFF) proprietary platform significantly improved the solubility of drugs that have poor water solubility.

In June 2021, TFF Pharmaceuticals held a conversation with Key Opinion Leaders to discuss its TFF Tacrolimus program for lung transplant as well as applications of its Thin Film Freezing technology for vaccine applications. View the presentation here.

Learn more about TFF’s Thin Film Freezing technology, its lead programs, TFF Voriconazole and TFF Tacrolimus, and its broad-reaching partnering strategy in the corporate overview video below.

August 12, 2021: TFF Pharmaceuticals Second Quarter 2021 Financial and Business Results Conference

TFF Pharmaceuticals Corporate Overview – March 2020